122 related articles for article (PubMed ID: 35772576)
1. Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial - PROFIT.
Zhou K; Renouf M; Perrocheau G; Magné N; Latorzeff I; Pommier P; Créhange G; Paumier A; Bera G; Martin J; Catton C; Bellanger M; Supiot S
Radiother Oncol; 2022 Aug; 173():306-312. PubMed ID: 35772576
[TBL] [Abstract][Full Text] [Related]
2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer.
He J; Wang Q; Hu Q; Li C
Front Oncol; 2022; 12():841356. PubMed ID: 36713549
[TBL] [Abstract][Full Text] [Related]
4. Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost-utility analysis alongside a randomized HYPO-RT-PC trial.
Sun S; Jonsson H; Salén KG; Andén M; Beckman L; Fransson P
Eur J Health Econ; 2023 Mar; 24(2):237-246. PubMed ID: 35587847
[TBL] [Abstract][Full Text] [Related]
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.
Shaikh T; Li T; Handorf EA; Johnson ME; Wang LS; Hallman MA; Greenberg RE; Price RA; Uzzo RG; Ma C; Chen D; Geynisman DM; Pollack A; Horwitz EM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):722-731. PubMed ID: 28244407
[TBL] [Abstract][Full Text] [Related]
7. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
9. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients.
Norkus D; Karklelyte A; Engels B; Versmessen H; Griskevicius R; De Ridder M; Storme G; Aleknavicius E; Janulionis E; Valuckas KP
Radiat Oncol; 2013 Sep; 8():206. PubMed ID: 24007322
[TBL] [Abstract][Full Text] [Related]
10. Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial.
Bruner DW; Pugh SL; Lee WR; Hall WA; Dignam JJ; Low D; Swanson GP; Shah AB; Malone S; Michalski JM; Dayes IS; Seaward SA; Nguyen PL; Pisansky TM; Chen Y; Sandler HM; Movsas B
JAMA Oncol; 2019 May; 5(5):664-670. PubMed ID: 30763425
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis comparing intensity-modulated radiotherapy with conformational radiotherapy (3D-RT) for prostate cancer in the brazilian health system.
Viani GA; Arruda CV; Oliveira R
Rev Assoc Med Bras (1992); 2021 Jun; 67(5):724-730. PubMed ID: 34550263
[TBL] [Abstract][Full Text] [Related]
12. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
13. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.
De Salas-Cansado M; Álvarez E; Olivares JM; Carrasco JL; Ferro MB; Rejas J
Soc Psychiatry Psychiatr Epidemiol; 2013 Jun; 48(6):985-96. PubMed ID: 23086587
[TBL] [Abstract][Full Text] [Related]
14. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.
Catton CN; Lukka H; Gu CS; Martin JM; Supiot S; Chung PWM; Bauman GS; Bahary JP; Ahmed S; Cheung P; Tai KH; Wu JS; Parliament MB; Tsakiridis T; Corbett TB; Tang C; Dayes IS; Warde P; Craig TK; Julian JA; Levine MN
J Clin Oncol; 2017 Jun; 35(17):1884-1890. PubMed ID: 28296582
[TBL] [Abstract][Full Text] [Related]
15. Conventional Versus Hypofractionated Radiation for High-Risk Prostate Cancer Patients (CHIRP): 24-Month Patient-Reported Outcomes of the Randomized Phase 2 CHIRP Trial.
Yang F; Ghosh S; Yee D; Patel S; Pervez N; Parliament M; Usmani N; Danielson B; Amanie J; Pearcey R; Field C; Fallone G; Murtha A
Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):99-107. PubMed ID: 35537578
[TBL] [Abstract][Full Text] [Related]
16. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials.
Royce TJ; Lee DH; Keum N; Permpalung N; Chiew CJ; Epstein S; Pluchino KM; D'Amico AV
Eur Urol Focus; 2019 Jul; 5(4):577-584. PubMed ID: 29221876
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
Amin NP; Sher DJ; Konski AA
Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
[TBL] [Abstract][Full Text] [Related]
19. Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England.
Nossiter J; Sujenthiran A; Cowling TE; Parry MG; Charman SC; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
J Clin Oncol; 2020 Mar; 38(7):744-752. PubMed ID: 31895608
[TBL] [Abstract][Full Text] [Related]
20. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
